Pharmalink’s maturing pipeline of products offers commercial partners opportunities to license high-value product candidates with strong clinical proof-of-concept data in a range of niche indications including renal disease, and for stem cell transplantation (haematology).
In addition to being based on high-quality science, Pharmalink’s projects are characterised by the rigour with which we define and maximise commercial potential and provide proof-of-value to our out-licensing partners. Projects proceed only if they address a clear market opportunity and where a product can be fully protected.
Our strong development capabilities and extensive experience ensure partners also have confidence that all aspects of the package have been managed to international standards: trial design, regulatory submissions, CMC issues and robust IP.
Pharmalink has two products in late-stage clinical development.
Busulipo™- the new standard in conditioning prior to hematopoietic stem cell transplantation. Pharmalink is actively seeking partners for Busulipo™ in all territories outside the Nordic region.
Nefecon® - the first pharmaceutical alternative to dialysis and transplantation for patients with IgA nephropathy. Pharmalink has a flexible partnering strategy for Nefecon®, a product with significant global sales potential, and anticipates seeking a commercial partner for Nefecon® in all territories.
To discuss project ideas, please contact Marek Poszepczynski, Business Development Director, +46 70 377 2273, , .
Link to corporate leaflet.
In June 2010, Pharmalink sold all IP and assets related to its Xepol® programme, the first medical treatment for post-polio syndrome, to Grifols, a group of companies which researches, develops, manufactures and markets products serving healthcare professionals and patients in over 90 countries around the world. The Xepol® concept was originally developed by scientists at Karolinska Institute in Sweden. Pharmalink, following positive preliminary clinical studies, sponsored a Phase III trial of Xepol® in post-polio syndrome, which demonstrated the product’s potential in the treatment of this lifelong and debilitating condition. All rights to the programme, including access to the data generated by Pharmalink, have been acquired by Grifols. Grifols will develop the product using all acquired assets, with Pharmalink assisting in providing the company with technology transfer and access to physician and patient organisations.